Abstract：Objective To investigate whether the concentration of circulating fibroblast growth factor 23 (FGF-23) is associated with new-onset atrial fibrillation (NAF) in general populations without chronic kidney disease (CKD).Methods A total of 1152 health checkup examinees who were free of CKD and atrial arrhythmia were selected between January 2012 and December 2015.Serum intact FGF-23 concentrations were measured using the Kainos 2-site ELISA method.NAF was diagnosed according to ECGs and hospital discharge records.All the subjects were followed up for three years.Multivariate logistic regression analysis was used to estimate the association between FGF-23 and NAF.Results The average age of these subjects was 56.6±5.7 years.44.2% (509) of them were males and 35 of them (3.0%) developed NAF during follow-up.These subjects were divided into four groups according to their FGF-23 levels.Elder males were more likely to have higher levels of FGF-23,who tended to have higher BMI,lower eGFR and higher serum phosphorus and PTH levels,and were more vulnerable to hypertension,diabetes mellitus,coronary artery disease,and left ventricular hypertrophy (LVH)(P<0.05).According to multivariable analysis,a higher baseline FGF-23 level was found to be associated with the risk of NAF (P<0.05).Conclusions Higher serum FGF-23 concentrations are associated with NAF in general populations without CKD.
Heine G H,Seiler S,Fliser D.FGF-23:the rise of a novel cardiovascular riskmarker in CKD[J].NDT,2012,27:3072-3081.
[2]
Dominguez J R,Shlipak M G,Whooley M A,et al.Fractional excretion ofphosphorus modifies the association between fibroblast growth factor-23 andoutcomes[J].J Am SocNephrol,2013,24:647-654.
[3]
Ix J H,Katz R,Kestenbaum B R,et al.Fibroblast growth factor-23 and death,heart failure,and cardiovascular events in community-living individuals:CHS(Cardiovascular Health Study)[J].J Am CollCardiol,2012,60:200-207.
[4]
Edvardsen T,Rosen B D,Pan L,et al.Regional diastolicdysfunction in individuals with left ventricular hypertrophy measuredby tagged magnetic resonance imaging-the Multi-Ethnic Study ofAtherosclerosis (MESA)[J].Am Heart J,2006,151:109-114.
[5]
Mirza M A I,Hansen T,Johansson L,et al.Relationship between circulating FGF23 and total body atherosclerosis in the community[J].NDT,2009,24(10):3125-3131.
[6]
Faul C,Amaral A P,Oskouei B,et al.FGF23 induces left ventricular hypertrophy[J].J ClinInvestigat,2011,121(11):4393-4408.
[7]
Miyamura M,Fujita S,Morita H,et al.Circulating fibroblast growth factor 23 has a u-shaped association with atrial fibrillation prevalence[J].Circ J,2015,79(8):1742.
[8]
Alonso A,Misialek J R,Eckfeldt J H,et al.Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation:the atherosclerosis risk in communities study[J].JAMA,2014,3(5):91-102.
[9]
Gutierrez O M,Januzzi J L,Isakova T,et al.Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease[J].Circulation,2009,119:2545-2552.
[10]
Faul C,Amaral A P,Oskouei B,et al.FGF23 induces left ventricular hypertrophy[J].J Clin Invest,2011,121:4393-4408.
[11]
Seiler S,Cremers B,Rebling N M,et al.The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation[J].Eur Heart J,2011,32(21):2688-2696.
Lim K,Lu T S,Molostvov G,et al.Vascular klotho de ciency potentiates the development of human artery calcication and mediates resistance to broblast growth fac- tor 23[J].Circulation,2012,125:2243-2255.
[14]
Meems L M,Cannon M V,Mahmud H,et al.The vitamin D receptor activator paricalcitolprevents fibrosis and diastolic dysfunction in a murine model of pressureoverload[J].J Steroid Biochem Mol Biol,2012,132:282-289.
[15]
Ky B,Shults J,Keane M G,et al.CRIC Study Investigators.FGF23 modifies therelationship between vitamin D and cardiac remodeling[J].Circ Heart Fail,2013,6:817-824.
[16]
Niwano S.Is circulating fibroblast growth factor 23 a surrogate marker or active mediator for the construction of atrial fibrillation substrate?[J].Circ J,2015,79(8):1685-1686.
2021, Vol. 32 
